Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
Complete SAD/MAD data from the Phase 1 trial of DISC-3405 in healthy volunteers were presented. In the SAD portion of this trial, healthy males and females ages 18 to 65 were given a single dose of ...
SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in ...
Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Disc Medicine (IRON – Research Report). The associated price ...
The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...
The AURORA study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial that enrolled 75 adult subjects with EPP. Subjects were randomized 1:1:1 to receive 20 mg of bitopertin (n=26) ...
Blood is one of the oldest drugs in the world, but after many decades of research, it is still not always clear when a blood ...
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...
This year at BuzzFeed, we spotlighted the voices of murderers, kidnapping survivors, and more. Below are some of the most ...
The treatment CS-101 uses innovative transformer Base Editing (tBE) technology to help people with severe diseases such as ...